Impact BioMedical, INC. Operating Cash Flow
Impact BioMedical, INC. (IBO) reported Operating Cash Flow of $6.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- Impact BioMedical, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $470.00K.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$464.00K.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $99.00K.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$613.00K.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$1.89M.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$2.85M.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$2.85M.
- Impact BioMedical, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$2.24M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $6.00K 10-Q · filed 2026-08-07 | $105.00K derived: sum of 3 quarters · filed 2026-08-07 | -$508.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | -$464.00K 10-Q · filed 2026-05-12 | -$365.00K derived: sum of 2 quarters · filed 2026-05-12 | -$978.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.67M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$514.00K derived: sum of 2 quarters · filed 2026-03-11 | -$1.21M derived: sum of 3 quarters · filed 2026-08-07 | -$1.89M 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | -$613.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.31M derived: sum of 2 quarters · filed 2026-08-07 | -$1.99M 10-Q · filed 2025-11-07 | -$2.98M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | -$694.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$1.38M 10-Q · filed 2026-08-07 | -$2.36M derived: sum of 3 quarters · filed 2026-08-07 | -$3.36M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | -$682.00K 10-Q · filed 2026-05-12 | -$1.67M derived: sum of 2 quarters · filed 2026-05-12 | -$2.67M derived: sum of 3 quarters · filed 2026-05-12 | -$3.05M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$986.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$1.99M derived: sum of 2 quarters · filed 2026-03-11 | -$2.37M derived: sum of 3 quarters · filed 2026-03-11 | -$2.85M 10-K · filed 2026-03-11 | -$3.92M 10-K · filed 2025-03-28 | |||
| 2024-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.39M derived: sum of 2 quarters · filed 2025-11-07 | -$1.87M 10-Q · filed 2025-11-07 | -$2.66M 10-Q · filed 2024-11-12 | -$2.30M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | -$385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$867.00K 10-Q · filed 2025-08-14 | -$1.38M 10-Q · filed 2024-08-13 | -$1.30M derived: sum of 3 quarters · filed 2025-08-14 | -$1.97M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$482.00K 10-Q · filed 2025-05-14 | -$712.00K 10-Q · filed 2024-05-10 | -$915.00K derived: sum of 2 quarters · filed 2025-05-14 | -$1.59M derived: sum of 3 quarters · filed 2025-05-14 | -$2.32M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$1.10M derived: sum of 2 quarters · filed 2025-03-28 | -$1.84M derived: sum of 3 quarters · filed 2025-03-28 | -$2.85M 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | -$671.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.40M derived: sum of 2 quarters · filed 2024-11-12 | -$2.42M 10-Q · filed 2024-11-12 | -$2.78M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$733.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.75M 10-Q · filed 2024-08-13 | -$2.11M derived: sum of 3 quarters · filed 2024-08-13 | -$2.91M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$1.01M 10-Q · filed 2024-05-10 | -$1.38M derived: sum of 2 quarters · filed 2024-05-10 | -$2.18M derived: sum of 3 quarters · filed 2024-05-10 | |||||
| 2022-12-31 | -$363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$1.17M derived: sum of 2 quarters · filed 2024-02-20 | -$2.24M 10-K · filed 2024-02-20 | |||||
| 2022-09-30 | -$802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.88M 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | -$1.08M 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |